{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T16:49:55Z","timestamp":1780505395482,"version":"3.54.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background\/Aims<\/jats:title>\n                <jats:p>Regression of liver fibrosis during antiviral therapy in chronic hepatitis B (CHB) patients has been demonstrated, but data on the influence of long-term treatment with tenofovir disoproxil fumarate (TDF) on liver stiffness (LS) measured by transient elastography are scarce. We aimed to investigate the changes in LS values during the 144-week TDF therapy in treatment-na\u00efve CHB patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This prospective observational study was conducted from April 2015 to July 2020 at CHA Bundang Medical Center. Laboratory tests and LS measurements were performed at baseline and repeated at weeks 12, 24, 48, 96, and 144. A significant decline in LS was defined as \u2265\u200930% decrease in LS value at week 96 from baseline.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 48 treatment-na\u00efve CHB patients initiating TDF therapy were screened, and 36 patients were included in the final analysis (median age, 46 [interquartile range, 34.5\u201355.8] years; 19 men [52.8%]). During TDF therapy, the median LS values decreased from 13.8\u00a0kPa at baseline to 8.7\u00a0kPa, 6.5\u00a0kPa, and 6.4\u00a0kPa at weeks 48, 96, and 144, respectively (all <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). At week 96, virological and biochemical responses were achieved in 34 (94.4%) patients and 20 (76.9%) patients, respectively. Moreover, 21 of 36 (58.3%) patients showed a significant decline in LS value. A higher baseline LS value was a single independent predictor for the reduction in LS value at week 96 from baseline (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>During the 144-week TDF therapy, LS values declined significantly in treatment-na\u00efve CHB patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12876-023-02846-9","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T13:02:17Z","timestamp":1686834137000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Changes in liver stiffness values assessed using transient elastography in chronic hepatitis B patients treated with tenofovir disoproxil fumarate: a prospective observational study"],"prefix":"10.1186","volume":"23","author":[{"given":"Heejin","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Bin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeonjung","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Eun","family":"Chon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi Na","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo Ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyu Sung","family":"Rim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong Gyu","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,15]]},"reference":[{"issue":"28","key":"2846_CR1","doi-asserted-by":"publisher","first-page":"773","DOI":"10.15585\/mmwr.mm6728a2","volume":"67","author":"Y Hutin","year":"2018","unstructured":"Hutin Y, Nasrullah M, Easterbrook P, Nguimfack BD, Burrone E, Averhoff F, Bulterys M. Access to Treatment for Hepatitis B Virus infection - Worldwide, 2016. MMWR Morb Mortal Wkly Rep. 2018;67(28):773\u20137.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"12","key":"2846_CR2","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/j.vaccine.2011.12.116","volume":"30","author":"JJ Ott","year":"2012","unstructured":"Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30(12):2212\u20139.","journal-title":"Vaccine"},{"issue":"1","key":"2846_CR3","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/hep.28156","volume":"63","author":"NA Terrault","year":"2016","unstructured":"Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. American Association for the study of liver D: AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261\u201383.","journal-title":"Hepatology"},{"issue":"1","key":"2846_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3350\/cmh.2021.0093","volume":"28","author":"SW Kim","year":"2022","unstructured":"Kim SW, Yoon JS, Lee M, Cho Y. Toward a complete cure for chronic hepatitis B: novel therapeutic targets for hepatitis B virus. Clin Mol Hepatol. 2022;28(1):17\u201330.","journal-title":"Clin Mol Hepatol"},{"issue":"3","key":"2846_CR5","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3350\/cmh.2020.0032","volume":"26","author":"T Inoue","year":"2020","unstructured":"Inoue T, Tanaka Y. Novel biomarkers for the management of chronic hepatitis B. Clin Mol Hepatol. 2020;26(3):261\u201379.","journal-title":"Clin Mol Hepatol"},{"issue":"4","key":"2846_CR6","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3350\/cmh.2020.0049","volume":"26","author":"HJ Yim","year":"2020","unstructured":"Yim HJ, Kim JH, Park JY, Yoon EL, Park H, Kwon JH, Sinn DH, Lee SH, Lee JH, Lee HW. Comparison of clinical practice guidelines for the management of chronic hepatitis B: when to start, when to change, and when to stop. Clin Mol Hepatol. 2020;26(4):411\u201329.","journal-title":"Clin Mol Hepatol"},{"issue":"11","key":"2846_CR7","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1056\/NEJMra031087","volume":"350","author":"D Ganem","year":"2004","unstructured":"Ganem D, Prince AM. Hepatitis B virus infection\u2013natural history and clinical consequences. N Engl J Med. 2004;350(11):1118\u201329.","journal-title":"N Engl J Med"},{"issue":"2","key":"2846_CR8","doi-asserted-by":"publisher","first-page":"276","DOI":"10.3350\/cmh.2022.0084","volume":"28","author":"Korean Association for the Study of the L","year":"2022","unstructured":"Korean Association for the Study of the L. KASL clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol. 2022;28(2):276\u2013331.","journal-title":"Clin Mol Hepatol"},{"issue":"3","key":"2846_CR9","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.cgh.2010.11.040","volume":"9","author":"ER Schiff","year":"2011","unstructured":"Schiff ER, Lee SS, Chao YC, Kew Yoon S, Bessone F, Wu SS, Kryczka W, Lurie Y, Gadano A, Kitis G, et al. Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol. 2011;9(3):274\u20136.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9865","key":"2846_CR10","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","volume":"381","author":"P Marcellin","year":"2013","unstructured":"Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Aguilar Schall R, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381(9865):468\u201375.","journal-title":"Lancet"},{"issue":"3","key":"2846_CR11","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/hep.23785","volume":"52","author":"TT Chang","year":"2010","unstructured":"Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, Safadi R, Lee SS, Halota W, Goodman Z, et al. Long-term entecavir therapy results in the reversal of fibrosis\/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52(3):886\u201393.","journal-title":"Hepatology"},{"issue":"3","key":"2846_CR12","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1002\/hep.22414","volume":"48","author":"P Marcellin","year":"2008","unstructured":"Marcellin P, Chang TT, Lim SG, Sievert W, Tong M, Arterburn S, Borroto-Esoda K, Frederick D, Rousseau F. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2008;48(3):750\u20138.","journal-title":"Hepatology"},{"issue":"1","key":"2846_CR13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1053\/gast.2003.50013","volume":"124","author":"JL Dienstag","year":"2003","unstructured":"Dienstag JL, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, Gardner S, Gray DF, Schiff ER. Histological outcome during long-term lamivudine therapy. Gastroenterology. 2003;124(1):105\u201317.","journal-title":"Gastroenterology"},{"issue":"7","key":"2846_CR14","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJM200102153440706","volume":"344","author":"AA Bravo","year":"2001","unstructured":"Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med. 2001;344(7):495\u2013500.","journal-title":"N Engl J Med"},{"issue":"1","key":"2846_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jhep.2008.10.014","volume":"50","author":"P Bedossa","year":"2009","unstructured":"Bedossa P, Carrat F. Liver biopsy: the best, not the gold standard. J Hepatol. 2009;50(1):1\u20133.","journal-title":"J Hepatol"},{"issue":"10","key":"2846_CR16","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1111\/j.1572-0241.2002.06038.x","volume":"97","author":"A Regev","year":"2002","unstructured":"Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, Feng ZZ, Reddy KR, Schiff ER. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 2002;97(10):2614\u20138.","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"2846_CR17","doi-asserted-by":"publisher","first-page":"e93160","DOI":"10.1371\/journal.pone.0093160","volume":"9","author":"YH Kuo","year":"2014","unstructured":"Kuo YH, Lu SN, Chen CH, Chang KC, Hung CH, Tai WC, Tsai MC, Tseng PL, Hu TH, Wang JH. The changes of liver stiffness and its associated factors for chronic hepatitis B patients with entecavir therapy. PLoS ONE. 2014;9(3):e93160.","journal-title":"PLoS ONE"},{"issue":"6","key":"2846_CR18","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1038\/ajg.2017.93","volume":"112","author":"YE Chon","year":"2017","unstructured":"Chon YE, Park JY, Myoung SM, Jung KS, Kim BK, Kim SU, Kim DY, Ahn SH, Han KH. Improvement of liver fibrosis after long-term antiviral therapy assessed by Fibroscan in Chronic Hepatitis B patients with Advanced Fibrosis. Am J Gastroenterol. 2017;112(6):882\u201391.","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"2846_CR19","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1111\/liv.12377","volume":"34","author":"MN Kim","year":"2014","unstructured":"Kim MN, Kim SU, Kim BK, Park JY, Kim DY, Ahn SH, Han KH. Long-term changes of liver stiffness values assessed using transient elastography in patients with chronic hepatitis B receiving entecavir. Liver Int. 2014;34(8):1216\u201323.","journal-title":"Liver Int"},{"issue":"11","key":"2846_CR20","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1111\/jvh.13345","volume":"27","author":"YE Chon","year":"2020","unstructured":"Chon YE, Jung KS, Ha Y, Kim MN, Lee JH, Hwang SG, Ahn SH, Kim DY, Han KH, Park JY. High body mass index hinders fibrosis improvement in patients receiving long-term tenofovir therapy in hepatitis B virus-related cirrhosis. J Viral Hepat. 2020;27(11):1119\u201326.","journal-title":"J Viral Hepat"},{"key":"2846_CR21","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ejphar.2017.03.063","volume":"806","author":"C Stasi","year":"2017","unstructured":"Stasi C, Salomoni E, Arena U, Corti G, Montalto P, Bartalesi F, Marra F, Laffi G, Milani S, Zignego AL, et al. Non-invasive assessment of liver fibrosis in patients with HBV-related chronic liver disease undergoing antiviral treatment: a preliminary study. Eur J Pharmacol. 2017;806:105\u20139.","journal-title":"Eur J Pharmacol"},{"issue":"7","key":"2846_CR22","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1111\/jgh.13294","volume":"31","author":"HM Wang","year":"2016","unstructured":"Wang HM, Hung CH, Lee CM, Lu SN, Wang JH, Yen YH, Kee KM, Chang KC, Tseng PL, Hu TH, et al. Three-year efficacy and safety of tenofovir in nucleos(t)ide analog-naive and nucleos(t)ide analog-experienced chronic hepatitis B patients. J Gastroenterol Hepatol. 2016;31(7):1307\u201314.","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"2846_CR23","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the study of Liver Diseases. Hepatology. 2018;67(1):328\u201357.","journal-title":"Hepatology"},{"issue":"3","key":"2846_CR24","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3350\/cmh.2021.0178","volume":"27","author":"SH Kang","year":"2021","unstructured":"Kang SH, Lee HW, Yoo JJ, Cho Y, Kim SU, Lee TH, Jang BK, Kim SG, Ahn SB, Kim H, et al. KASL clinical practice guidelines: management of nonalcoholic fatty liver disease. Clin Mol Hepatol. 2021;27(3):363\u2013401.","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"2846_CR25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.4292\/wjgpt.v7.i1.91","volume":"7","author":"PE Chang","year":"2016","unstructured":"Chang PE, Goh GB, Ngu JH, Tan HK, Tan CK. Clinical applications, limitations and future role of transient elastography in the management of liver disease. World J Gastrointest Pharmacol Ther. 2016;7(1):91\u2013106.","journal-title":"World J Gastrointest Pharmacol Ther"},{"issue":"3","key":"2846_CR26","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1002\/hep.25993","volume":"57","author":"J Boursier","year":"2013","unstructured":"Boursier J, Zarski JP, de Ledinghen V, Rousselet MC, Sturm N, Lebail B, Fouchard-Hubert I, Gallois Y, Oberti F, Bertrais S, et al. Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology. 2013;57(3):1182\u201391.","journal-title":"Hepatology"},{"issue":"8","key":"2846_CR27","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/ajg.2014.145","volume":"109","author":"SS Kim","year":"2014","unstructured":"Kim SS, Hwang JC, Lim SG, Ahn SJ, Cheong JY, Cho SW. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis. Am J Gastroenterol. 2014;109(8):1223\u201333.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"2846_CR28","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3350\/cmh.2015.21.1.41","volume":"21","author":"SK Jung","year":"2015","unstructured":"Jung SK, Kim KA, Ha SY, Lee HK, Kim YD, Lee BH, Paik WH, Kim JW, Bae WK, Kim NH, et al. Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naive and nucleos(t)ide analogue-experienced chronic hepatitis B patients. Clin Mol Hepatol. 2015;21(1):41\u20138.","journal-title":"Clin Mol Hepatol"},{"issue":"2","key":"2846_CR29","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. Electronic address eee, European Association for the study of the L: EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370\u201398.","journal-title":"J Hepatol"},{"issue":"1","key":"2846_CR30","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/hep.20506","volume":"41","author":"M Ziol","year":"2005","unstructured":"Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, de Ledinghen V, Marcellin P, Dhumeaux D, Trinchet JC, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology. 2005;41(1):48\u201354.","journal-title":"Hepatology"},{"issue":"2","key":"2846_CR31","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/j.1478-3231.2008.01802.x","volume":"29","author":"P Marcellin","year":"2009","unstructured":"Marcellin P, Ziol M, Bedossa P, Douvin C, Poupon R, de Ledinghen V, Beaugrand M. Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int. 2009;29(2):242\u20137.","journal-title":"Liver Int"},{"issue":"2","key":"2846_CR32","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1097\/01.qai.0000194238.15831.c7","volume":"41","author":"V de Ledinghen","year":"2006","unstructured":"de Ledinghen V, Douvin C, Kettaneh A, Ziol M, Roulot D, Marcellin P, Dhumeaux D, Beaugrand M. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV\/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr. 2006;41(2):175\u20139.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"2846_CR33","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1002\/hep.21151","volume":"43","author":"C Corpechot","year":"2006","unstructured":"Corpechot C, El Naggar A, Poujol-Robert A, Ziol M, Wendum D, Chazouilleres O, de Ledinghen V, Dhumeaux D, Marcellin P, Beaugrand M, et al. Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. Hepatology. 2006;43(5):1118\u201324.","journal-title":"Hepatology"},{"issue":"12","key":"2846_CR34","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1111\/j.1872-034X.2011.00869.x","volume":"41","author":"E Ogawa","year":"2011","unstructured":"Ogawa E, Furusyo N, Murata M, Ohnishi H, Toyoda K, Taniai H, Ihara T, Ikezaki H, Hayashi T, Kainuma M, et al. Longitudinal assessment of liver stiffness by transient elastography for chronic hepatitis B patients treated with nucleoside analog. Hepatol Res. 2011;41(12):1178\u201388.","journal-title":"Hepatol Res"},{"issue":"6","key":"2846_CR35","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.jhep.2019.02.006","volume":"70","author":"ES Park","year":"2019","unstructured":"Park ES, Lee AR, Kim DH, Lee JH, Yoo JJ, Ahn SH, Sim H, Park S, Kang HS, Won J, et al. Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients. J Hepatol. 2019;70(6):1093\u2013102.","journal-title":"J Hepatol"},{"issue":"4","key":"2846_CR36","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1007\/s12072-010-9189-z","volume":"4","author":"J Fung","year":"2010","unstructured":"Fung J, Lai CL, But D, Hsu A, Seto WK, Cheng C, Wong DK, Yuen MF. Reduction of liver stiffness following resolution of acute flares of chronic hepatitis B. Hepatol Int. 2010;4(4):716\u201322.","journal-title":"Hepatol Int"},{"issue":"2","key":"2846_CR37","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1097\/MEG.0b013e328332d2fa","volume":"22","author":"M Vigano","year":"2010","unstructured":"Vigano M, Massironi S, Lampertico P, Iavarone M, Paggi S, Pozzi R, Conte D, Colombo M. Transient elastography assessment of the liver stiffness dynamics during acute hepatitis B. Eur J Gastroenterol Hepatol. 2010;22(2):180\u20134.","journal-title":"Eur J Gastroenterol Hepatol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-023-02846-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-023-02846-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-023-02846-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T13:02:57Z","timestamp":1686834177000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-023-02846-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,15]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2846"],"URL":"https:\/\/doi.org\/10.1186\/s12876-023-02846-9","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,15]]},"assertion":[{"value":"14 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol followed the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the Institutional Review Boards of CHA Bundang Medical Center (IRB number: BD2014-178). The purpose of the study was fully stated to the participants and all participants signed a written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Lee YB reports receiving research grant from Samjin Pharmaceuticals and Yuhan Pharmaceuticals; Dr. Hwang SG reports receiving research grant from Gilead Sciences. No other potential conflict of interest relevant to this article was reported.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"210"}}